Tonix Pharmaceuticals (NASDAQ: TNXP) announced it will deliver an oral presentation on its investigational TNX-801 vaccine platform and lead a working group session at the World Vaccine Congress Europe, taking place Oct. 19-21, 2026, in Amsterdam, Netherlands. The company’s presentation, scheduled for Oct. 21 at 1:15 p.m. CEST, will address the safety and efficacy of TNX-801, a live, attenuated, minimally replicative horsepox virus-based vaccine platform being developed to protect against mpox and other infectious diseases. Tonix will also lead a working group session titled “Vectored Vaccine Platforms: From Design to Improving Efficacy” on Oct. 20 at 11:30 a.m. CEST. For additional details, the full press release is available at https://ibn.fm/BHVjU.
The significance of this announcement lies in the ongoing global need for effective vaccines against mpox and other emerging infectious diseases. Mpox, formerly known as monkeypox, has caused outbreaks worldwide, and current vaccine options are limited. TNX-801’s minimally replicative horsepox platform is designed to induce a strong immune response while potentially offering a better safety profile than existing vaccines. Presenting at the World Vaccine Congress Europe, a key gathering of vaccine developers, researchers, and public health officials, positions Tonix to gain visibility and feedback from the scientific community. The working group session further underscores the company’s expertise in vectored vaccine platforms, which are increasingly important for rapid response to outbreaks.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg), the company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R). Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
For investors, the conference presentation could serve as a catalyst for increased awareness of Tonix’s immunology pipeline, which complements its commercial CNS products. The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP.
This announcement was distributed through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. The full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
